Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
Professor Daniel Hayes Joins Stratipathâs Scientific Advisory Board
Stratipath is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the companyâs Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipathâs innovative solutions in breast cancer precision diagnostics.
Stratipath Secures Spot on Prestigious 33-List of Top Innovative Tech Companies for Third Consecutive Year
Stratipath has been recognized as one of the Gold Companies on NyTeknik – First with news about technology and IT. and AffĂ€rsvĂ€rldenâs prestigious 33-list â for the maximum three consecutive years!
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göranâs Hospital
Capio St Göranâs Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
Unilabs Sverige and St. Göranâs Hospital are soon adopting Stratipath Breast for breast cancer risk profiling.
Johan Hartman is a guest at the Johnson & Johnson podcast âVi forskar för livetâ (âResearch for Lifeâ). The episode, titled âPrecision Medicine is the Future of Healthcare â But Do We Have the Skills Needed?â
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the worldâs largest biotechnology company and the global leader in in-vitro diagnostics.
Webinar: Prognostic Tools in Breast Cancer Care
In collaboration with iBreastBook, Johan Hartman, co-founder of Stratipath, participated in a webinar focused on predictive and prognostic tools in breast cancer care. Johan delivered an insightful lecture on: âAI-Based Image Analysis: A Cost-Effective Alternative to Genomic Profilingâ. We were honored to have an excellent lineup of speakers and panelists who shared their expertise:– Abeer […]
Stratipath Joins Forces with Colombian Pathology Leaders to Advance Digital Pathology
Stratipath is thrilled to announce our active role in advancing Digital Pathology in Colombia, driven by the collaborative efforts between the Swedish Association of Pathology and the Colombian Association of Pathology. Our Co-founder and CMO, Professor Johan Hartman, has been at the forefront of these discussions, bringing invaluable insights from Sweden’s experience with Digital Pathology. […]
A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breastâthe first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.
Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman
Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman